15 October 2020

IQ-AI Ltd

(“IQ-AI” or the “Company”)

IB Stroke™

IQ-AI, Ltd is pleased to announce the launch of IB Stroke, marking the completion of a key new product introduction that further increases IQ-AI’s footprint in neuro imaging. IB Stroke is immediately available as a set of workflows processed by the highly flexible and customizable IB Rad Tech platform. It provides users with the flexibility to process both MR and CT perfusion image sets, thus allowing use in any imaging environment. The IB Stroke output may be used by clinicians to help determine the usefulness of treating the patient with clot-busting drugs – drugs which can potentially save oxygen-starved brain tissue but bring with them a host of potential side-effects.  

In the USA alone, approximately 800,000 people experience a stroke each year and stroke remains a leading cause of disability. Current annual stroke related costs are $46 billion and are projected to increase to $94 billion by 2035. By capitalizing on existing software capabilities and regulatory clearances of the IB Clinic® software suite, IB Stroke is available in both Europe (CE Marked) and the US (FDA-cleared) markets. IQ-AI intends to serve this sizable market through annual subscriptions to IB Stroke.

“The development team at IB met a very aggressive timeline and delivered on providing an extremely efficient and foundational software solution for stroke assessment,” said Trevor Brown, IQ-AI’s CEO. “With the on-schedule completion of IB Stroke, resources will now shift to the development of IB Trax™ which will also leverage core IB algorithms including Delta T1 maps”.

IB recently submitted an application to the US Patent and Trademark Office for their Delta T1 mapping process. Delta T1 maps are a foundational in the assessment of brain images that use a contrast agent.

The Directors of the Company accept responsibility for the contents of this announcement.

-ENDS-

For further information, please contact:

ABOUT Imaging Biometrics, LLC

Imaging Biometrics®, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB’s advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company’s website at   www.imagingbiometrics.com.

Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.